Deutsche Bank Initiates Coverage On Neumora Therapeutics with Hold Rating, Announces Price Target of $13
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Neena Bitritto-Garg has initiated coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Hold rating and set a price target of $13.

December 12, 2023 | 10:06 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Deutsche Bank has initiated coverage on Neumora Therapeutics with a Hold rating and a price target of $13.
The initiation of coverage by a major bank like Deutsche Bank generally brings a stock into the spotlight, potentially increasing its visibility among investors. However, the 'Hold' rating suggests a neutral outlook, implying that the stock is fairly valued at its current price. The price target of $13 provides a reference point for investors but does not suggest significant upside or downside, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100